True Appoints Kate Vanek as General Manager, International
19.4.2022 09:03:00 EEST | Business Wire | Press release
True, the fastest-growing global platform of innovative talent management products and services, announced today it has appointed Kate Vanek as general manager, international. Kate joins True from BlackRock where she held the dual responsibility of CFO of EMEA and COO of global finance.
In her role, Kate will work closely with True’s global leadership to enhance and expand the firm’s international executive search business and broader platform of talent management products and services including Thrive, Synthesis, and AboveBoard. Kate is London-based and will oversee the international business across EMEA and APAC, which today includes True's offices in Amsterdam, Berlin, Dubai, London, Melbourne, Shanghai, Singapore, Stockholm, Sydney and Tel Aviv.
“Kate has a passion for talent management and a dynamic, inspirational leadership style,” said Joe Riggione, True co-founder and co-CEO. “She’s a high-performance operator who combines her personal and business experiences to connect people and complex global organizations. She is an impressive leader with an extraordinary track record, and we are lucky to have her.”
“I’m thrilled to be joining True during this period of expansion, and I’m excited to help propel True’s vision to build the global talent management firm of the future,” Kate commented. “True’s special culture and commitment to investing in its people, combined with their world-class executive search expertise and cutting-edge platform make it a place I couldn’t be more proud to join.”
“Kate's experience in strategic business building prepares her to expand our offerings globally to meet the needs of our clients who rely on True’s talent expertise and platform to help them grow and thrive,” said Brad Stadler, True co-founder and co-CEO.
Kate Vanek, True’s GM, International
Kate’s background has rich diversity of experience in finance, strategy and business operations, M&A, investor relations, DE&I initiatives, and leadership development. She has managed global teams in leadership roles across a range of industries from financial services, data science, consumer behavior measurement to industrials.
ABOUT TRUE
True is a platform of products and services driving the intelligence behind talent management:
True Search
Global recruitment for board members, c-suite executives, VPs, directors, and other strategic talent. We focus on investment firms, their portfolio companies and public companies seeking transformative growth.
Thrive
Collaborative, real-time talent relationship management software and information services for search firms, in-house recruiters and VC/PE firms looking to make better hiring decisions.
Synthesis
A multi-layered approach to leadership assessment and development, which combines the evaluation methods of elite military units, executive coaching techniques and agile methodology principles.
AboveBoard
True co-founded AboveBoard, a diversity-focused startup bringing unparalleled solutions to the critical need to bring more women and executives of color to leadership roles. With AboveBoard's two-way platform, members get unique visibility to hundreds of opportunities while companies get access to qualified candidates.
True Equity
True Equity provides exposure to high-quality venture capital and growth equity investments. As a value-added talent partner, True Equity makes direct investments alongside premier investors. True Equity Fund I participates in Series A and B investments. True Equity Growth Fund II focuses on late stage venture and growth equity companies.
Vera
Vera is a family of investment funds that backs exceptional entrepreneurs and companies dedicated to changing our collective future through technology at the pre-seed, seed, early, and late stages.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220418005587/en/
Contact information
Press:
Sarah Mikhailova
Vice President of Communications
sarah@trueplatform.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 17:19:00 EEST | Press release
Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com
BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 17:15:00 EEST | Press release
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “Following the U.S. approval in August, these longer-term data provide further evidence supporting TEVIMBRA plus ZIIHERA and chemotherapy as the new standard of care in all first-line HER2-positive advanced gastroesophageal adenocarcinoma patients, regardless of PD-L1 sta
inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 16:00:00 EEST | Press release
inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a leading Central Asian economy, this gives the companies a clear basis to assess autonomous ride-hailing in practice. The three companies will evaluate the technical, operational, regulatory and
Brenus Pharma's Novel In Vivo Immunotherapy STC-1010 Shows Safety, Activating T Cells in First-Line MSS Metastatic Colorectal Cancers With 2 Complete Responses.23.10.2026 15:50:00 EEST | Press release
Brenus Pharma, a clinical-stage biotech company, announced first data from the Phase Ia dose escalation of BreAK CRC-001. Nine unresectable patients were treated; 89% had liver metastases and 89% KRAS-mutant tumors, a population refractory to immunotherapy. Median follow-up: 8 months (1–14; data cut-off 6/08/2026). 95% of metastatic colorectal cancers are pMMR/MSS tumors, poorly immunogenic and resistant to immunotherapy. STC-1010, the company’s lead in vivo DC-engager, is designed to make these “cold” tumors visible to immune cells. Safety: no dose-limiting toxicity, only grade 1–2 related adverse events. Clinical activity (seven evaluable patients, RECIST 1.1): 100% disease control, 57% objective response rate (4/7). 43% of patients became operable (3/7): two with no evidence of disease afterward. Molecular profile: ctDNA dropped by up to 97% within two months, TP53 and KRAS mutations near undetectable. Immune activity (first six patients): STC-1010 regimen nearly quadrupled cytotoxi
Takeda Announces Arcotatug Tavatecan (TAK-921) Demonstrated Statistically Significant and Clinically Meaningful Improvements in Overall Survival and Progression-Free Survival in Phase 3 Advanced Gastric Cancer Study23.10.2026 14:30:00 EEST | Press release
Takeda(TSE:4502/NYSE:TAK)announced positive results from the Phase 3 G-HOPE-001 study (NCT06238843) of arcotatug tavatecan (TAK-921; Innovent R&D code: IBI343) in patients with Claudin (CLDN)18.2-positive, previously treated, advanced gastric or gastroesophageal junction adenocarcinoma (G/GEJA). Results from two prespecified interim analyses, which were shared in a late-breaking oral presentation at the 2026 European Society for Medical Oncology (ESMO) Congress, showed the study met its dual primary endpoints of overall survival (OS) and progression-free survival (PFS). Gastric cancer is a leading cause of cancer-related death worldwide, and outcomes are particularly poor once the disease is advanced.1 Because treatment options are limited for people whose cancer continues to progress after multiple therapies, there is a significant need for new targeted therapies.2 CLDN18.2, a protein found at abnormally high levels on the surface of certain cancer cells, has emerged as a key biomarke
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom